BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Pharm Country

  These worms have rhythm

  There’s a rhythm to developing life. Growing from a tiny cell cluster into an adult organism takes precise timing and control.

  December 27, 2023

   · 

  2 min read
• Deals

  Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.

  Visiox Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market.

  December 27, 2023

   · 

  12 min read
• Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02

  Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd jointly announce that the development of a tri-specific T cell engager for an intracellular target achieved milestone progress.

  December 27, 2023

   · 

  6 min read
• Drug Development

  Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

  Enveric Biosciences announced the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results.

  December 27, 2023

   · 

  6 min read
• Policy

  Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a Transitional Pass-Through (TPT) Payment for the DETOUR™ System

  Endologix LLC announces that the U. S. Centers for Medicare & Medicaid Services granted a Transitional Pass-Through Payment for the DETOUR System, effective January 1, 2024.

  December 27, 2023

   · 

  4 min read
• BioCapital

  AbelZeta to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  AbelZeta Pharma, Inc. announced that Tony Liu, Chairman and CEO, will present an update on the Company at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.

  December 27, 2023

   · 

  2 min read
• Genetown

  Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

  Bluejay Diagnostics, Inc., announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients.

  December 27, 2023

   · 

  4 min read
• Pharm Country

  Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced that Geno Germano, CEO and President of Elucida Oncology, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

  December 27, 2023

   · 

  1 min read
• Biotech Beach

  RxSight, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

  December 27, 2023

   · 

  1 min read
• Biotech Beach

  Axonics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.

  December 27, 2023

   · 

  1 min read